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Abstract
Introduction: Decreased diffusing capacity of the lung for carbon monoxide (DLCO) is observed in some idiopathic pulmonary 
arterial hypertension (IPAH) patients, but its clinical significance is uncertain. We aimed to assess clinical correlates and progno-
stic significance of low DLCO in IPAH patients. 
Material and methods: In the group of 65 IPAH patients the cut off value for low DLCO was set up based on histogram as < 
55% of predicted value. Demographic data, exercise capacity, lung function tests, hemodynamic parameters and survival of the 
patients were compared depending on DLCO value.
Results: Low DLCO was found in 18% of the patients, and it was associated with male sex, older age, worse functional status and exer-
cise capacity, and higher prevalence of coronary artery disease. Low DLCO carried a 4-fold increase of death risk in 5-year perspective.
Conclusions: Low DLCO was a marker of worse functional capacity and increased risk of death in studied IPAH patients.
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Introduction
The risk stratification in idiopathic pul-
monary arterial hypertension (IPAH) patients 
is currently based on hemodynamic [1−4] and 
functional parameters such as: functional class 
[1, 4], distance of six-minute walking test [2, 
3, 5], peak exercise oxygen consumption [6, 7]. 
The other factors predictive of survival are bio-
markers of myocardial injury (troponin) [8] and 
myocardial strain (BNP/NT-proBNP) [9]. Mild to 
moderate disturbances in blood gases and lung 
function tests, such as hypoxemia, hypocapnia, 
impaired maximal midexpiratory airflow were 
found in IPAH patients, but their clinical signifi-
cance was not well defined [5, 10, 11]. Diffusing 
capacity of the lung for carbon monoxide (DLCO) 
impairment has been already described in pul-
monary arterial hypertension (PAH), mainly in 
connective tissue disease with both interstitial 
and vascular lung pathology [12−14]. The preva-
lence and clinical significance of DLCO impair-
ment in IPAH is less obvious [15, 16]. Thus the 
aim of the present study was to assess clinical 
correlates and prognostic significance of low 
DLCO in IPAH patients.
Pneumonologia i Alergologia Polska 2016, vol. 84, no. 2, pages 87–94 
88 www.pneumonologia.viamedica.pl
Material and methods
Study population
The study population consisted of 65 IPAH 
patients, 49 women and 16 men, median age 
43 years (17−74 years), who were diagnosed in 
the pulmonary hypertension reference center 
(Department of Chest Medicine at the Institute 
of Tuberculosis and Lung Diseases in Warsaw, 
Poland) in the period of 1998−2006. The study 
was approved by the Human Ethics Committee of 
the National Institute of Tuberculosis and Lung 
Diseases. Written informed consent was obtained 
from every patient.
Chronic thromboembolic pulmonary hyper-
tension was excluded based on the results of chest 
computed tomography (CT) angiography and lung 
scintigraphy in all of the patients. High resolution 
chest CT scans (HRCT) were also analyzed to 
exclude interstitial lung disease. 
Right heart catheterization (RHC) was per-
formed in all of the patients (in 9 patients the 
first RHC was performed outside of our centre). 
The diagnosis of pulmonary arterial hypertension 
(PAH) was based on finding of mean rest pulmona-
ry artery pressure (mPAP) higher than 25 mm Hg 
measured directly, in absence of elevated pulmo-
nary artery wedge pressure (PAWP ≤ 15 mm Hg), 
and with pulmonary vascular resistance higher 
than 3 Wood units. Vasoreactivity testing was per-
formed with nitric oxide or with inhaled iloprost. 
In the patients who were receiving calcium chan-
nel blockers (CCB) upon referral (28 cases), the 
drug was stopped for 12−24 hours before RHC and 
vasoreactivity testing. Positive response was defi-
ned as the decrease of mPAP of at least 10 mm Hg 
and to the value lower than 40 mm Hg, with no 
change or with the increase of cardiac output 
(CO). In responders, CCB were continued in 
maximal tolerated doses, in non-responders the 
CCB were stopped. 
IPAH was recognized after the exclusion of 
all secondary causes of PAH. Connective tissue 
disease was excluded based on lack of the signs 
and symptoms of systemic disease and absence 
of specific antinuclear antibodies. PAH associated 
with portal hypertension was excluded based on 
negative medical history, absence of signs of portal 
hypertension or liver disease on abdomen ultra-
sonography, and normal serum hepatic enzymes. 
In all patients pulmonary function testing 
(PFT) was performed as a part of a differential 
diagnosis of PH. 
The mean time span between PFT and RHC 
was 19,25 (± 33.08) days. Comparison of PFT and 
RHC results was performed only in those 50 pa-
tients in whom both procedures were performed 
within the short time span (30 days). 
Exercise capacity was measured with 6-minu-
te walking test (6MWT), performed on a corridor 
in accordance with the ATS guidelines [17]. Oxy-
gen saturation (SaO2) was measured before (SaO2 
pre-test) and in the 6th minute of the test (SaO2 6 
min). The results were expressed as the distance 
covered during the test, and SaO2 6 min. 
In 9 patients with RHC performed in other 
centre, PAH-specific therapy was introduced be-
fore referral to our department. Nevertheless, fur-
ther treatment and its subsequent modifications 
were performed at our centre. In the remaining 
patients the treatment was started by our team. 
The first drug introduced was endothelin receptor 
antagonist (in 38 patients), or prostacycline ana-
log (in 18 patients), or sildenafil (in 8 patients). 
Regular face to face control visits were performed. 
The adherence to treatment was very good. The 
subsequent decisions to add the medication of 
different class were made in cases of significant 
clinical worsening, after assessment of 6MWT, 
NT-proBNP, echocardiography and RHC results. 
At the end of the study 44 patients were receiving 
monotherapy with PAH specific drug, 20 patients 
— combined PAH-specific treatment (2−3 drugs 
belonging to different classes). 
The patients were followed up for at least 
60 months from PFT. During that period of time 
34 (52%) patients died due to end-stage right 
heart insufficiency, 3 underwent lung transplan-
tation (observations censored at the time of the 
operation), 2 were lost to follow-up (both after 
10 months), 26 patients stayed alive.
Pulmonary Function Testing
PFT was performed with use of MasterLab 
v.3.26 equipment (until January 2002) and Master 
Screen Body Plethysmograph (after January 2002), 
both Jaeger (Germany), with accordance to ERS 
guidelines [18−22]. Spirometry, whole body plethy-
smography, and single-breath diffusing capacity for 
carbon monoxide measurements were performed. 
DLCO results were corrected for hemoglobin levels. 
Predicted values for forced expiratory volume 
in 1 second (FEV1) and forced vital capacity (FVC) 
were taken from Falaschetti et al. [23], and from 
ERS, for all other parameters [19]. Values corre-
sponding to 5th and 95th percentile were used to 
define lower and upper limits of normal (LLN and 
ULN, respectively) [24]. An obstructive ventila-
tory defect was defined as FEV1/VCmax (maximum 
vital capacity) below LLN. Its severity was based 
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Figure 1. Histogram of DLCO%pred.
on the FEV1 as follows: FEV1 ≥ 70% pred. — mild, 
and FEV1 60-69 % pred. — moderate obstruction. 
A restrictive ventilatory defect was diagnosed in 
patients with TLC < LLN, and was recognized 
as mild if TLC was ≥ 70% pred., or moderate if 
TLC was 60−69% pred. [24]. Hyperinflation was 
defined as RV (residual capacity)/TLC > ULN [24].
Statistical analysis
All analyses were performed using STATISTI-
CA 6.0 (Statsoft) computer software. The results 
were expressed as the median values (range), un-
less otherwise stated. Arbitrary used cut off value 
for low DLCO was calculated from the histogram. 
Fisher’s chi-square test was used for comparison 
of categorical variables and U Mann-Whitney test 
for continuous variables. Survival analysis was 
performed with Kaplan-Meier method. Survivals 
in groups were compared with F-Cox test. The 
prognostic value of selected variables was tested 
by univariate Cox proportional hazard regression 
analysis, and expressed as hazard ratios (HR) with 
95% confidence intervals (95% CIs). P ≤ 0.05 was 
considered statistically significant.
Results
RHC revealed the following hemodynamic 
indices (mean ± SD): pulmonary artery pressure 
systolic/diastolic/mean −83.4 (± 19.1)/39.3 (± 
10.4)/55.9 (± 12.7) mm Hg, pulmonary artery 
wedge pressure — 9.6 (± 1.9) mm Hg, right atrial 
pressure — 8.5 (± 4.8) mm Hg, stroke volume 
−57.3 (± 17.0) ml, cardiac output −4.4 (± 1.1) 
l/min, cardiac index –2.6 (± 0.7) l/min*m2, pul-
monary vascular resistance index — 6.9 (± 2.9) 
jW*m2, total pulmonary vascular resistance index 
–8.0 (± 3.2) jW*m2, mixed venous blood saturation 
(SaO2mv) –56.8 (± 8.0)%. 17 out of 65 (26%) patients 
were responders in acute vasoreactivity testing. 
WHO functional class (FC) was: I — in one 
patient, II — in 40 patients (61%), III — in 21 
(32%) and IV — in 2 patients (3%), status of 
1 patient was not established.
Mean resting partial oxygen (PaO2) and partial 
carbon dioxide (PaCO2) pressures in arterialized 
capillary blood were 65.9 (± 14.7) mm Hg and 
31.4 (± 4.17) mm Hg, respectively. Mean 6MWT 
distance was 377.5 (± 110) m, desaturation exce-
eding 5% was observed in 23 (35%) of the patients.
Serum NT-proBNP (N-terminal pro-brain 
natriuretic peptide) was measured in 32 patients,
Mean concentration was 2186.7 (± 2235.2) pg/ml.
Median DLCO value for the whole group of 
IPAH patients was 72.0 (22.7−117.9) % pred., 
mean value was 69.1 (± 20.0) % pred. The DLCO 
% pred. histogram showed a double-peak contour 
(Fig. 1). Based on it, the patients were divided 
in two groups: a group with DLCO < 55% pred. 
consisting of 12 (18%) patients, and a group 
with DLCO ≥ 55% pred. comprising remaining 
53 (82%) patients.
The comparison of demographic data, co-
morbidities and type of PH-specific treatment is 
presented in Table 1. The patients with low DLCO 
were significantly older, and with significantly 
higher prevalence of coronary artery disease than 
the patients with DLCO ≥ 55% pred. There were 
more males, smokers, and patients with higher 
BMI in the group with low DLCO compared to 
the other, but the differences were not significant. 
HRCT results were similar in both groups 
and revealed the presence of: ill-defined centrilo-
bular nodules (8% and 12% respectively), focal 
ground glass opacities (16% and 25% respecti-
vely), centrilobular emphysema (16% and 8% 
respectively), post-tuberculous scaring (8% and 
16% respectively). In the remaining patients no 
parenchymal lesions were described on chest 
HRCT. No expiratory air-trapping was found in 
the patients with centrilobular nodules or with 
focal ground glass opacifications.
The comparison of pulmonary function tests 
and blood gases between the two groups of pa-
tients is presented in Table 2. Airway obstruction 
was found in 5 patients with DLCO < 55% pred. 
(42%) and 9 patients with DLCO ≥ 55% pred. 
(17%), difference was not significant. Isolated 
MMEF < LLN was found in 2 patients with DLCO 
< 55% pred. (17%) and 12 patients with DLCO 
≥ 55% pred. (22%). Hyperinflation was found in 
6% of patients with DLCO ≥ 55% pred. and none 
in the group with DLCO < 55% pred. 
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Table 2.  The results of pulmonary function tests, arterialized blood gases analysis in 65 IPAH patients depending on DLCO 
% predicted value
Characteristic DLCO <  55% pred. DLCO ≥ 55% pred. p*
n Median (IQR) n Median (IQR)
FEV1, %pred. 12 109.1 (95.6−122.0) 53 107.3 (98.9−122.6) 0.07
VC, % pred. 12 88.8 (80.1−102.2) 53 99.5 (83.2−109.0) NS
bronchial obstruction
n (%)
12 5 (42%) 53 9 (17%) NS
Isolated MMEF < LLN n (%) 12 2 (17%) 53 12 (22%) NS
TLC, % pred. 12 111.7 (93.4−117.1) 53 110.6 (99.8−116.4) NS
TLC < LLN n (%) 12 1 (8%) 53 1 (2%) NS
RV/TLC, % pred. 12 107 (84.5−125.5) 53 105 (57.7 137.5) NS
RV/TLC > ULN
n (%)
12 0 (0%) 53 3(6%) NS
PaO2, mm Hg 12 51.5 (46.4−56.2) 53 71.7 (60.8−80.8) 0.00003
PaCO2, mm Hg 12 29.1 (26.7−31.3) 53 31.8 (29.8−34.2) 0.065
SaO2, % 12 89.1 (86.3−91) 53 95.3 (92.3−96.5) 0.00003
DLCO — diffusion capacity for carbon monoxide; FEV1 — forced expiratory volume in 1 second; IQR — interquartile range; Kco — carbon monoxide transfer coefficient; 
MMEF — maximum midexpiratory flow; ns — not significant; ULN — upper limit of normal; LLN — lower limit of normal; PaCO2 — partial carbon dioxide pressure; PaO2 
— partial oxygen pressure; pred. — predicted; RV — residual volume; SaO2 — oxyhemoglobin saturation, TLC — total lung capacity; VC — maximum vital capacity
Both PaO2 and hemoglobin oxygen saturation 
(SaO2) were significantly lower in the group with 
low DLCO compared to the other. 
The comparison of 6MWT, functional class, 
NT-proBNP, and right heart catheterization para-
meters in both groups is presented in Table 3. In 
the patients with low DLCO, significantly shorter 
6MWT distance, lower SaO2 at the end of 6MWT, 
and higher percentage of class III and IV patients, 
were observed compared to the other patients.
Median NT-pro BNP concentration was signi-
ficantly higher in the group with low DLCO than 
Table 1. Comparison of demographic characteristics, comorbidities and PH-specific treatment in IPAH patients with DLCO 
< 55% pred. and DLCO ≥ 55% pred. 
Characteristic DLCO <  55% pred. DLCO ≥ 55% pred. p*
n Median (IQR) n Median (IQR)
Gender: Male:Female 12 1:1 53 1:4 0.059
Smokers (past and present), n (%) 12 7 (58%) 53 15 (28%) NS
Age, years 12 58 (48−68) 53 41 (29−45) 0.0008
Arterial hypertension, n (%) 12 3 (25%) 53 5 (10%) NS
Coronary artery disease, n (%) 12 5 (42%) 53 0 (0%) 0.0002
Astma,well controlled, n (%) 12 0 (0%) 53 3 (5%) NS
COPD Gold stage 2, n (%) 12 2 (17%) 53 0 (0%) 0.07
BMI kg/m2 12 27.5(19−40.7) 53 24(18.6−44.5) 0.06
Prostanoids, n (%) 12 5 (42%) 53 21 (40%) NS
Endothelin-1 antagonists, n (%) 12 8 (67%) 53 25 (47%) NS
Phosphodiesterase-5 inhibitors 
n (%)
12 4 (33%) 53 23 (43%) NS
Riociguat, n (%) 12 0 (0%) 53 2 (4%) NS
BMI — body mass index; COPD — chronic obstructive pulmonary disease
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Table 3. The results of 6MWT, functional class, NT-proBNP, and hemodynamic parameters in 65 IPAH patients depending 
on DLCO % predicted value
Characteristic DLCO < 55% pred. DLCO ≥ 55% pred. p*
n Median (IQR) n Median (IQR)
6MWT distance, m 12 284 (190−388) 52 395.5 (366−459) 0.01
6MWT SaO2 pre-test, % 10 91 (87−93) 51 97 (95−98) 0.0001
6MWT SaO2 6 min, % 10 82 (75−87) 48 94 (90−97.5) 0.0006
Functional class III and IV n (%) 12 9 (75%) 52 14 (27%) 0.005
NT-proBNP, pg/ml 10 3005 (1929−5093) 22 1202 (166.9−2031) 0.016
RAPm, mm Hg 10 9 (7−12) 40 8 (4−11) NS
PAPm, mm Hg 10 52.5 (48−55) 40 56.5 (46.5−64.5) NS
PAWP, mm Hg 10 10 (5−14) 40 10 (6−14) NS
CO, l/min 10 4.47 (3.56−5.09) 40 4.19 (3.61−5.11) NS
CI, l/min/m2 10 2.32 (2.13−2.57) 40 2.53 (2.09−2.86) NS
PVRI, jW*m2 10 10.36 (7.87−12.54) 40 10.31 (8.44−15.48) NS
SaO2mv, % 10 57 (43−59) 40 57 (51.5−64) NS
Responders n (%) 10 2 (20%) 40 10 (25%) NS
CI — cardiac index; CO — cardiac output; DLCO — diffusion capacity for carbon monoxide; IQR — interquartile range, ns-not significant; NT-proBNP — N-terminal 
pro-brain natriuretic peptide; PAPm — mean pulmonary artery pressure; pred. — predicted; PAWP — pulmonary artery wedge pressure; PVRI — pulmonary vascular 
resistance index; SaO2-oxyhemoglobin saturation; SaO2mv — mixed venous oxygen saturation; 6MWT — six-minute walk test; RAPm — mean right atrial pressure.
Figure 2. Comparison of survival rates between patients with DLCO < 55%pred. and with DLCO ≥ 55%pred.
in the other (3005 vs. 1202 pg/ml, p = 0.016). 
There were, however, no significant differences 
between the two groups concerning hemodyna-
mic indices and the percentage of responders to 
acute vasoreactivity test (Table 3).
Mean survival time for the whole group was 
56 (± 33) months. The cumulative survival rates 
were: 1 year — 97%, 2 years — 88%, 3 years — 
77%, 4 years — 63%, 5 years — 57%. Survival 
curves of IPAH patients depending on DLCO % 
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Table 4. Univariate survival analysis in 65 IPAH patients
Parameter n HR −95%CI +95%CI p
Age, years 65 1.01 0.99 1.04 NS
Male gender 65 2.34 1.18 4.63 0.015
SaO2 % 65 0.81 0.76 0.87 0.0000002
SaO2 < 90% 65 5.44 2.62 11.29 0.000005
PaO2, mm Hg 65 0.94 0.92 0.97 0.00002
PaO2 < 60 mm Hg 65 2.71 1.40 5.22 0.003
PaCO2 mm Hg 65 0.93 0.86 1.02 NS
DLCO < 55%pred 65 3.92 1.79 8.60 0.0006
FEV1/VCmax, %pred. 65 1.00 0.96 1.03 NS
6MWT distance, per 10 m 65 0.96 0.93 1.00 0.03
NT-proBNP, per 100 pg/ml 34 1.03 1.01 1.05 0.001
RAPm, mm Hg 50 1.04 0.97 1.11 NS
PAPm, mm Hg 50 1.00  0.98 1.03  NS
CO, l/min 50 0.93 0.69 1.27 NS
PVRI, jW*m2 50 1.01 0.90 1.14 NS
SaO2mv < 63 mm Hg 50 4.63 1.39 15.39 0.01
CI — confidence interval; CO — cardiac output; DLCO — diffusion capacity for carbon monoxide; FEV1 — forced expiratory volume in 1 second; HR — hazard ratio; 
MMEF — maximum midexpiratory flow; ns — not significant; NT-proBNP — N-terminal pro-brain natriuretic peptide; PaCO2 — partial carbon dioxide pressure; PAPm 
— mean pulmonary artery pressure; pred. — predicted; PaO2 — partial oxygen pressure; pred. — predicted; PVRI — pulmonary vascular resistance index; SaO2 — 
oxyhemoglobin saturation; SaO2mv — mixed venous oxygen saturation; 6MWT — six-minute walk test
pred. are presented in Figure 2. The prognosis 
was significantly worse for patients with DLCO < 
55 % pred. compared to those with DLCO ≥ 55% 
pred., median survival time was 30.5 months vs 
66.4 months, respectively, p = 0.004.
Univariate Cox proportional hazard regres-
sion revealed significant influence of male gender, 
PaO2, SaO2, DLCO < 55% pred., 6MWT distance, 
NT-pro BNP serum concentration, and SaO2mv < 
63% pred., on survival (Table 4). DLCO, SaO2, and 
SaO2mv were the strongest prognostic indicators. 
The risk of death was increased 4 times if DLCO 
was less than 55% pred., 5 times if SaO2 was 
less than 90%, and more than 4 times if SaO2mv 
was less than 63%. We failed to demonstrate the 
independent prognostic significance of DLCO, 
probably due to small number of patients with 
low DLCO and the strong correlation between 
DLCO% pred. and SaO2 (r = 0,43, p = 0,0003).
Discussion
Low DLCO (< 55% pred.) was diagnosed in 
18% of IPAH patients in our study. These patients 
were significantly older, and the percentage of ma-
les and prevalence of coronary artery disease were 
higher among them in comparison to the others. 
Other authors also found the association between 
low DLCO and older age and male gender [10, 25, 
26]. Such characteristics could suggest the influence 
of left heart disease and/or cigarette smoking on 
DLCO. The influence of chronic left heart failure on 
PFT was reported recently by Minasian et al., who 
found DLCO impairment and airway obstruction in 
44-58% of patients [27]. Nevertheless, in none of our 
patients pulmonary artery wedge pressure exceeded 
15 mm Hg, thus significant left heart disease was 
excluded. Moreover, PAWP in the patients with 
DLCO < 55% pred. was comparable with those from 
the group with DLCO ≥ 55% pred. The influence 
of cigarette smoking cannot be completely ruled 
out, even if statistically there was no significant 
difference in share of smokers between two groups 
distinguished on the base of DLCO in our study.
A well-known cause of severe DLCO decrease 
in PAH patients is pulmonary veno-occlusive dise-
ase (PVOD) [28]. Inhomogeneous lung attenuation 
in form of ill-defined centrilobular nodules and fo-
cal ground glass opacifications seen on HRCT scans 
in some of our patients could suggest the presence 
of this condition. However, no other radiological 
signs of PVOD such as thickened interlobular sep-
ta, enlarged mediastinal lymph nodes and pleural 
effusion were found. What’s more, inhomogeneo-
us lung attenuation was observed with similar 
frequency in the patients with low DLCO and 
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the remaining ones. The presence of various lung 
attenuation disturbances on HRCT was described 
by other authors in 5−10% of IPAH patients [28] 
and was also reported by our group previously [29].
Lung diseases coexisting with IPAH should 
be always taken into account as the cause of low 
DLCO. In the recommendations published as 
a result of the Fifth World Symposium on Pulmo-
nary Hypertension, the proposed criteria to exc-
lude significant lung disease were as follows [30]:
TLC ≥ 70%pred., FVC ≥ 70%pred., and FEV1 
≥ 60% pred. 
No significant fibrosis and/or emphysema on 
chest HRCT. 
All of the patients from our group meet 
these criteria.
Nevertheless, bronchial obstruction was 
diagnosed in 14 of our 65 IPAH patients (22%). 
The non-significant tendency to more frequent 
bronchial obstruction was noticed in the pa-
tients with low DLCO compared to the others 
(42% and 17%, respectively). The obstructive 
lung diseases were diagnosed in 5 patients only 
(2 patients with COPD in the group with DLCO 
< 55% pred, and 3 patients with asthma in the 
group with DLCO ≥ 55%pred.). In the remaining 
patients the cause of bronchial obstruction 
remained unclear. Bronchial pathology in the 
course of IPAH has to be taken into account. 
The decrease of peripheral airflow and de-
crease of DLCO were previously reported in 
IPAH patients without coexisting lung diseases, 
suggesting the influence of vascular pathology on 
ventilation parameters or the coexisting changes 
in small bronchi in the course of IPAH [10, 11]. 
Nevertheless, in our group of patients, the percen-
tage of those with isolated MMEF < LLN was the 
same in the group with low and with higher DLCO. 
Noteworthy is also the fact that the degree 
of DLCO impairment didn’t reflect the extent 
of vascular lesions in our study group of IPAH 
patients. The comparison of pulmonary vascular 
resistance as well as the remaining hemodyna-
mic parameters between the group with low 
DLCO and the other group didn’t reveal any 
differences. The percentage of responders in the 
acute hemodynamic test was also comparable 
between the groups. Our results are in line with 
data of Sun et al. [10] and Chandra et al. [13], 
who found no relationship between DLCO and 
hemodynamic variables, either.
Despite being not correlated with hemody-
namic profile, low DLCO was clearly associated 
with worse functional status: higher percentage 
of WHO III and IV class patients, shorter 6MWT 
distance, and greater desaturation on exertion. Mo-
reover, significantly higher median NT-proBNP 
values were found in the patients with low 
DLCO comparing to the others. Therefore, it 
was not surprising that DLCO < 55% pred. 
was a significant negative prognostic indicator 
for survival in our group and carried a 4-fold 
increase of death risk in 5-year perspective. We 
reported similar finding on negative prognostic 
value of low DLCO in IPAH patients in three 
years follow-up, previously [31]. In study of 
Chandra et al. [13], DLCO < 43% pred. was 
associated with 2.7-fold increase of risk of 
death. Low DLCO also appeared as a negative 
prognostic factor in larger groups of patients in 
national PAH registries. Benza et al. [1] reported 
that DLCO ≤ 32% pred. was one of the negative 
prognostic factors in the patients enrolled to RE-
VEAL Registry. Lee et al. [3] found relationship 
between DLCO and survival in the UK Registry. 
The patients were enrolled into the present 
study between 1998 and 2006. Therefore the li-
mitation might be related to suboptimal treatment 
due to unavailability of some PAH specific drugs 
at that period of time. Nevertheless, the survival 
reported in the present study was slightly better 
than the results reported by Humbert et al. based 
on French Registry (PAH patients enrolled in 
2002−2003) [2] and better that the survival in USA 
registry (PAH patients enrolled in 1982−2006) [14]. 
Moreover, there were no significant differences 
between the type of treatment in the patients with 
low DLCO compared to the remaining ones. Thus 
we suppose that the treatment type didn’t influ-
ence survival in the present study. 
Summary
In the present study, low DLCO value 
(< 55% pred.) was found in 18% of IPAH pa-
tients, and it was significantly associated with 
older age, higher prevalence of coronary artery 
disease, worse functional status and worse 
exercise capacity. Patients with low DLCO had 
4-fold increase of death-risk as compared to the 
patients with higher DLCO values.
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